OBJECTIVE： To observe the clinical efficacy of sitagliptin combined with benazepril in the treatment of diabetic nephropathy （DN）. METHODS： Sixty DN patients admitted to our hospital during Sept. 2014-Jun. 2015 were divided into sitagliptin group， benazepril group， drug combination group according to random number table， with 20 cases in each group. Based on routine treatment， sitagliptin group was given sitagliptin 100 mg orally， qd； benazepril group was given Benazepril 10 mg orally， qd； drug combination group was given sitagliptin 100 mg+benazepril 10 mg orally， qd. The drug dosage would be doubled if the blood pressure of patients in 3 groups had not yet reached the standard. Treatment course of 3 groups lasted for 12 weeks. The levels of 24 h urine protein， IL-6 and Cys-C were measured in 3 groups before and after treatment. Clinical efficacies and the occurrence of ADR were observed. RESULTS： Total response rate of drug combination group （90.00％） was significantly higher than those of sitagliptin group （65.00％） and benazepril group （70.00％）； there was statistically significance （P＜0.05）. After treatment， the levels of 24 h urine protein， IL-6 and Cys-C in 3 groups were significantly lowered， compared to before treatment； those of drug combination group was significantly lower than those of other 2 groups； there was statistically significance （P＜0.05）. There was no statistical significance in above indexes between sitagliptin group and benazepril group （P＞0.05）. No obvious ADR was found in 3 groups during treatment. CONCLUSIONS： Both sitagliptin and benazepril can decrease the levels of 24 h urine protein， IL-6 and Cys-C， while drug combination shows better effect and clinical response rate， and does not influence the safety of drug use.